Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline | Journal of Clinical Oncology
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis | HTML
Breast Cancer Survival Rate: Prognosis by Age and More
First-line Durvalumab Improves Survival
Survival in patients with HR+/HER2− metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study | British Journal of Cancer
Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China - ScienceDirect
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial - Annals of Oncology
Chemo or Hormone Therapy Result in Similar Survival for Women with Breast Cancer - CancerConnect
Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy | Anticancer Research
Effects of Alkalization Therapy on Chemotherapy Outcomes in Metastatic or Recurrent Pancreatic Cancer | Anticancer Research
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients - European Journal of Cancer
PDF) Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton
Frontiers | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials | Oncology
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients - European Journal of Cancer
Breast cancer - The Lancet
Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis | Scientific Reports
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis - The Lancet Oncology
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort - ESMO Open
Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer - The Lancet Oncology
Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China - ScienceDirect
Impact of deviation from guideline recommended treatment on breast cancer survival in Asia | Scientific Reports
